JO3265B1 - مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض - Google Patents

مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض

Info

Publication number
JO3265B1
JO3265B1 JOP/2009/0466A JOP20090466A JO3265B1 JO 3265 B1 JO3265 B1 JO 3265B1 JO P20090466 A JOP20090466 A JO P20090466A JO 3265 B1 JO3265 B1 JO 3265B1
Authority
JO
Jordan
Prior art keywords
treatment
pyridyloxyindoles
vegf
inhibitors
disease
Prior art date
Application number
JOP/2009/0466A
Other languages
English (en)
Inventor
Meredith Erik
Rao Chang
David Artman Gerald Iii
Matthew Elliott Jason
J Powers James
Liu Donglei
Ma Fupeng
Miranda Karl
Ji Nan
Mainolfi Nello
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42034535&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3265(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3265B1 publication Critical patent/JO3265B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع بمركبات عضوية جديدة لها الصيغة (I) (I) واستخدامها في علاج جسم حيوان أو إنسان، وتركيبات صيدلانية تتضمن مركب الصيغة (I) وباستخدام مركب الصيغة (I) لتحضير تركيبات صيدلانية للاستخدام في علاج أمراض معتمدة على كيناز بروتين، بشكل خاص أمراض تكاثرية، على سبيل المثال علاج أمراض الورم وأمراض الأوعية الحديثة داخل العين.
JOP/2009/0466A 2008-12-09 2009-12-06 مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض JO3265B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20124308P 2008-12-09 2008-12-09
US23334109P 2009-08-12 2009-08-12

Publications (1)

Publication Number Publication Date
JO3265B1 true JO3265B1 (ar) 2018-09-16

Family

ID=42034535

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0466A JO3265B1 (ar) 2008-12-09 2009-12-06 مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض

Country Status (39)

Country Link
US (6) US8242125B2 (ar)
EP (1) EP2376478B1 (ar)
JP (1) JP5580330B2 (ar)
KR (1) KR101345956B1 (ar)
CN (2) CN103193773B (ar)
AR (1) AR074499A1 (ar)
AU (1) AU2009326110B9 (ar)
BR (1) BRPI0922552A2 (ar)
CA (1) CA2745922C (ar)
CL (1) CL2011001378A1 (ar)
CO (1) CO6382119A2 (ar)
CR (1) CR20110270A (ar)
CU (1) CU24097B1 (ar)
CY (1) CY1119091T1 (ar)
DK (1) DK2376478T3 (ar)
EA (1) EA019681B1 (ar)
EC (1) ECSP11011113A (ar)
ES (1) ES2633959T3 (ar)
HN (1) HN2011001593A (ar)
HR (1) HRP20171075T1 (ar)
HU (1) HUE035292T2 (ar)
IL (1) IL213068A (ar)
JO (1) JO3265B1 (ar)
LT (1) LT2376478T (ar)
MX (1) MX2011006093A (ar)
MY (1) MY155649A (ar)
NZ (2) NZ601656A (ar)
PE (1) PE20110835A1 (ar)
PL (1) PL2376478T3 (ar)
PT (1) PT2376478T (ar)
RS (1) RS56076B1 (ar)
SG (1) SG171784A1 (ar)
SI (1) SI2376478T1 (ar)
SV (1) SV2011003939A (ar)
TN (1) TN2011000263A1 (ar)
TW (1) TWI429640B (ar)
UY (1) UY32302A (ar)
WO (1) WO2010066684A2 (ar)
ZA (1) ZA201103759B (ar)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AU2011322597B2 (en) * 2010-10-27 2015-09-10 Novartis Ag Dosing regimes for the treatment of ocular vascular disease
CN102786469B (zh) * 2011-05-18 2016-09-14 中国医学科学院药物研究所 邻吡啶酰肼衍生物及其制法和药物组合物与用途
EA027113B1 (ru) * 2012-05-04 2017-06-30 Новартис Аг Регуляторы пути комплемента и их применение
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
KR101315227B1 (ko) * 2012-05-30 2013-10-07 엘지디스플레이 주식회사 터치스크린 일체형 표시장치 및 그 구동 방법
WO2014002051A2 (en) * 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
WO2014002053A1 (en) * 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JP6155332B2 (ja) * 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
ES2712190T3 (es) * 2012-06-28 2019-05-09 Novartis Ag Moduladores de la vía del complemento y sus usos
WO2014002057A1 (en) * 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EP2867229B1 (en) * 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
EA201590200A1 (ru) * 2012-07-12 2015-08-31 Новартис Аг Модуляторы пути активации комплемента и их применение
CN103570616B (zh) * 2012-07-18 2017-10-20 中国医学科学院药物研究所 N′‑直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途
CN105229003B (zh) 2013-03-14 2017-03-15 诺华股份有限公司 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
WO2014154173A1 (zh) * 2013-03-28 2014-10-02 广州康睿生物医药科技有限公司 一种抗血管新生化合物
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
US10174006B2 (en) * 2013-06-06 2019-01-08 Novartis Ag Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
JP6522502B2 (ja) 2013-07-29 2019-05-29 協和発酵キリン株式会社 Ｗｎｔシグナル阻害剤
US9676728B2 (en) 2013-10-30 2017-06-13 Novartis Ag 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
JP6248269B2 (ja) * 2014-02-06 2017-12-20 株式会社Ｊｏｌｅｄ 表示装置
JP2017206437A (ja) * 2014-08-18 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 ４−アミノピリジン誘導体
WO2016137506A1 (en) * 2015-02-27 2016-09-01 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
WO2017003862A1 (en) * 2015-07-01 2017-01-05 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
JP6857651B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体
EP3371174B1 (en) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives
JP6857653B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体
CR20180255A (es) 2015-11-06 2018-06-22 Hoffmann La Roche Derivados de indolin-2-ona
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE068971T2 (hu) 2016-04-04 2025-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei
SI3458456T1 (sl) 2016-05-18 2021-04-30 Loxo Oncology, Inc. Priprava (S)-N-(5-((R)-2-(2,5-difluorofenil) pirolidin-1-il) pirazolo (1,5-A) pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JP2019534269A (ja) 2016-10-14 2019-11-28 ノバルティス アーゲー Ｃｓｆ−１ｒの阻害剤を使用して眼疾患を治療するための方法
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN108586454B (zh) * 2018-02-13 2021-02-26 沈阳药科大学 四氢吡啶并[4,3-d]嘧啶类衍生物及其用途
CN110386892B (zh) * 2018-04-16 2020-08-18 新发药业有限公司 一种4-氟-5-羟基-2-甲基-1h-吲哚的制备方法
CN110483482A (zh) * 2018-05-15 2019-11-22 北京诺诚健华医药科技有限公司 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
KR20210151818A (ko) * 2019-04-12 2021-12-14 내셔날 헬스 리서치 인스티튜트 치료 용도를 위한 키나제 억제제로서의 헤테로사이클릭 화합물
MX2022007171A (es) 2019-12-27 2022-08-22 Schroedinger Inc Compuestos cíclicos y métodos de uso de estos.
WO2022033472A1 (zh) * 2020-08-11 2022-02-17 河南迈英诺医药科技有限公司 Fgfr抑制剂化合物及其用途
EP4211140A1 (en) 2020-09-10 2023-07-19 Schrödinger, Inc. Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
IL314186A (en) 2022-01-24 2024-09-01 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
US20250223277A1 (en) 2022-04-01 2025-07-10 Novartis Ag Complement factor b inhibitors and uses thereof
WO2025059027A1 (en) 2023-09-11 2025-03-20 Schrödinger, Inc. Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001231710A1 (en) 2000-02-09 2001-08-20 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
GB0126902D0 (en) 2001-11-08 2002-01-02 Novartis Ag Organic compounds
PE20040522A1 (es) * 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MXPA05001536A (es) 2002-08-30 2005-04-19 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
AR041992A1 (es) * 2002-11-06 2005-06-08 Smithkline Beecham Corp Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla
SE0302324D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
GB0420520D0 (en) * 2004-09-15 2004-10-20 Novartis Ag Organic compounds
GB0421525D0 (en) * 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
EP2574340A3 (en) 2006-04-07 2013-04-17 Novartis AG Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
TWI440638B (zh) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物

Also Published As

Publication number Publication date
KR101345956B1 (ko) 2014-02-06
PL2376478T3 (pl) 2017-10-31
HUE035292T2 (en) 2018-05-02
SG171784A1 (en) 2011-07-28
CU20110129A7 (es) 2012-01-31
KR20110098799A (ko) 2011-09-01
US8242125B2 (en) 2012-08-14
WO2010066684A2 (en) 2010-06-17
US20120245187A1 (en) 2012-09-27
CN103193773B (zh) 2014-12-10
US20130005750A1 (en) 2013-01-03
NZ593030A (en) 2013-11-29
WO2010066684A3 (en) 2010-10-14
CU24097B1 (es) 2015-06-30
ZA201103759B (en) 2012-01-25
SI2376478T1 (sl) 2017-07-31
RS56076B1 (sr) 2017-10-31
CA2745922C (en) 2017-06-27
US20130005751A1 (en) 2013-01-03
TWI429640B (zh) 2014-03-11
AU2009326110B9 (en) 2013-10-31
CA2745922A1 (en) 2010-06-17
CN103193773A (zh) 2013-07-10
US8541432B2 (en) 2013-09-24
TN2011000263A1 (en) 2012-12-17
EA019681B1 (ru) 2014-05-30
HRP20171075T1 (hr) 2017-10-06
CN102307870B (zh) 2014-06-18
US8501756B2 (en) 2013-08-06
US8492393B2 (en) 2013-07-23
DK2376478T3 (en) 2017-07-31
PT2376478T (pt) 2017-06-30
EP2376478B1 (en) 2017-04-19
CR20110270A (es) 2011-06-28
IL213068A (en) 2017-02-28
US20130005753A1 (en) 2013-01-03
US20130012529A1 (en) 2013-01-10
CN102307870A (zh) 2012-01-04
AU2009326110B2 (en) 2013-09-12
US8431584B2 (en) 2013-04-30
TW201026686A (en) 2010-07-16
JP5580330B2 (ja) 2014-08-27
IL213068A0 (en) 2011-07-31
AR074499A1 (es) 2011-01-19
LT2376478T (lt) 2017-07-10
CO6382119A2 (es) 2012-02-15
UY32302A (es) 2010-07-30
CL2011001378A1 (es) 2011-11-25
US20100168082A1 (en) 2010-07-01
JP2012511535A (ja) 2012-05-24
EA201100873A1 (ru) 2011-12-30
US8486954B2 (en) 2013-07-16
MY155649A (en) 2015-11-13
ES2633959T3 (es) 2017-09-26
CY1119091T1 (el) 2018-01-10
AU2009326110A1 (en) 2011-06-23
SV2011003939A (es) 2011-07-28
BRPI0922552A2 (pt) 2021-11-03
NZ601656A (en) 2013-11-29
ECSP11011113A (es) 2011-07-29
HN2011001593A (es) 2014-01-20
EP2376478A2 (en) 2011-10-19
MX2011006093A (es) 2011-06-21
PE20110835A1 (es) 2011-11-25

Similar Documents

Publication Publication Date Title
JO3265B1 (ar) مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
MY148246A (en) Bicyclic amides as kinase inhibitors
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
MX2010014233A (es) Compuestos quimicos 251.
IN2012DN01453A (ar)
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2012001838A (es) Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX2009005622A (es) Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores.
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
MX2014003194A (es) 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
IN2012DN00953A (ar)
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
MX2008013477A (es) Compuestos biciclicos de tetrahidropirrol.
WO2006138589A3 (en) Opioid receptor ligands
UA100390C2 (en) Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors